Technical Analysis for REGN - Regeneron Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
A 751.30 -1.11% -8.46
REGN closed down 1.11 percent on Wednesday, March 22, 2023, on 50 percent of normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Flat Flat

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
20 DMA Support Bullish -1.11%
Gapped Up Strength -1.11%
50 DMA Support Bullish -1.05%
Crossed Above 20 DMA Bullish -1.05%
50 DMA Support Bullish 0.49%
NR7 Range Contraction 0.49%
Down 3 Days in a Row Weakness 0.49%
Fell Below 20 DMA Bearish 0.21%
50 DMA Support Bullish 0.21%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible NR7 about 10 hours ago
Possible Inside Day about 10 hours ago
20 DMA Support about 14 hours ago
Fell Below 20 DMA about 14 hours ago
10 DMA Support 1 day ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Regeneron Pharmaceuticals, Inc. Description

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company offers EYLEA injection for the treatment of neovascular age-related macular degeneration and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its product candidates in clinical development stage consist of EYLEA for the treatment of ophthalmologic diseases; and ZALTRAP for oncology. The company's earlier stage clinical programs include various human monoclonal antibodies, such as REGN88 for rheumatoid arthritis; REGN727 for low-density lipoprotein cholesterol reduction; REGN668 for atopic dermatitis and allergic asthma; REGN421, REGN910, and REGN1400 for oncology; REGN475 for the treatment of pain; REGN846 for atopic dermatitis; and REGN1500, REGN1033, and REGN1154. It also conducts preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. The company distributes its products through third party service providers. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA outside the United States. The company was founded in 1988 and is headquartered in Tarrytown, New York.


Sector: Healthcare
Industry: Biotechnology
Keywords: S&P 500 Medicine Biotechnology Biopharmaceutical Nasdaq 100 Immunology Infectious Diseases Clinical Development Pain Antibodies Bone Inflammation Monoclonal Antibodies Cardiovascular Disease Disorders Clinical Research Ophthalmology Rheumatoid Arthritis Macular Degeneration Vascular Disease Asthma Colorectal Cancer Cholesterol Breakthrough Therapy Macular Edema Syndromes Dermatitis Lipoprotein Atopic Dermatitis Cartilage Angiogenesis Human Monoclonal Antibodies Metastatic Colorectal Cancer Regeneron Allergic Asthma Immune Diseases Muscle Disease Muscle Diseases

Is REGN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 800.48
52 Week Low 538.01
Average Volume 586,878
200-Day Moving Average 691.80
50-Day Moving Average 749.01
20-Day Moving Average 759.54
10-Day Moving Average 753.79
Average True Range 16.24
RSI 47.92
ADX 12.56
+DI 18.93
-DI 23.16
Chandelier Exit (Long, 3 ATRs) 736.56
Chandelier Exit (Short, 3 ATRs) 774.38
Upper Bollinger Bands 780.84
Lower Bollinger Band 738.24
Percent B (%b) 0.31
BandWidth 5.61
MACD Line 0.65
MACD Signal Line 1.96
MACD Histogram -1.3124
Fundamentals Value
Market Cap 78.78 Billion
Num Shares 105 Million
EPS 27.29
Price-to-Earnings (P/E) Ratio 27.53
Price-to-Sales 6.24
Price-to-Book 5.26
PEG Ratio 0.96
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 771.37
Resistance 3 (R3) 773.50 768.95 768.03
Resistance 2 (R2) 768.95 763.84 767.88 766.91
Resistance 1 (R1) 760.12 760.68 757.85 757.99 765.79
Pivot Point 755.57 755.57 754.43 754.50 755.57
Support 1 (S1) 746.74 750.46 744.47 744.61 736.81
Support 2 (S2) 742.19 747.30 741.12 735.69
Support 3 (S3) 733.36 742.19 734.58
Support 4 (S4) 731.23